Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate-amodiaquine in Malnourished Children with Malaria
NCT01204411Phase 4Withdrawn
- Sponsor
- Illumina
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artesunate and amodiaquine in Plasmodium falciparum malaria, sponsored by Illumina. Primary endpoint: PCR adjusted clinical and parasitological efficacy at 42 days. Status: withdrawn.
02
Drugs
artesunateamodiaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01204411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204411.